Yes Risiko, I know that. But by what I have said, I can understand your response. Enjoy reading your posts mate.
As for the possibility of a mention on US Sixty Minutes - Wow. To think a technically preclinical company could get some exposure makes a big statement. Not all that long ago, this would have been totally inconceivable.
But even if Novogen is overlooked in the program, that is out of our control. If there is a link however between the Benzinga report and the Nasdaq spike - and I tend to agree with Floridavd1 that it seems likely - and we are made mention of then brilliant PR and well deserved recognition of Dr K and the other scientists and the clinical team driving this thing.
NRT Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
